With all the heightened interest in checkpoint inhibitors of late, I wanted to continue my series on what did we learn from the updated data at ESMO that was different from ASCO? Last week we discussed gastric and bladder cancers, this week it’s the turn of lung cancer, or more specifically, non-small cell lung cancer (NSCLC).
Adenocarcinoma associated with gastric (stomach) cancer is more common in Asian than North America people and tends to occur in men over 40. Risk factors include smoking, H. pylori, and diet. Asian countries also tend to have larger amounts of smoked foods, salted fish and meat, and pickled vegetables in their diet. Nitrates and nitrites are substances commonly found in cured meats and can be converted by bacteria, such as H. pylori, into compounds that have been shown to cause stomach cancer in animals.
Cancer immunotherapy, the ability to harness the body’s own immune system to fight cancer, is showing early promise in bladder cancer.
It’s a funny old world sometimes… I was planning to post a mini series on immuno-oncology presentations from ESMO this week and review what we had learned from the new data, good and not so good. This morning’s sudden announcement from Genentech regarding their latest collaboration is therefore rather timely:
We spend a lot of time in the poster halls at scientific and medical meetings such as European Society for Medical Oncology (ESMO) Congress in Madrid because that’s where the action is in terms of finding nuggets of promising preclinical and early clinical data. You can also spot new trends emerging earlier this way.
One of the sessions that stood out for me at the recent European Society for Medical Oncology (ESMO) Congress in Madrid was a Special Symposium on “Advances in Precision Medicine of Metastatic Colorectal Cancer.”
It’s a while since we discussed ALK+ lung cancer, but with new data coming out at ESMO last week, this is a good time to take stock and see what’s happening with the next generation inhibitors in a post crizotinib (Xalkori) world. These include ceritinib (Zykadia), alectinib and Ariad’s AP26113, which just received Breakthrough Therapy Designation from the FDA.
At the 2014 ESMO Congress in Madrid, Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute, Boston) presented the results of the Tokai Pharmaceuticals (NASDAQ $TKAI) ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.
Madrid – it’s Day 3 of ESMO 2014 (#ESMO14), the annual Congress of the European Society for Medical Oncology, and the last day when we will be publishing a live blog from the meeting.
Madrid – it’s Day 2 of the European Society for Medical Oncology (Twitter #ESMO14) annual meeting and the Congress is now in full swing. Today one of the highlights is the Presidential Session that takes place this afternoon. It’s where all attendees have the opportunity to hear what ESMO think is the most noteworthy data at the meeting, irrespective of the type of cancer.